These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21559452)

  • 1. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
    Zhang L; Bhasin M; Schor-Bardach R; Wang X; Collins MP; Panka D; Putheti P; Signoretti S; Alsop DC; Libermann T; Atkins MB; Mier JW; Goldberg SN; Bhatt RS
    PLoS One; 2011 Apr; 6(4):e19144. PubMed ID: 21559452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Allen E; Walters IB; Hanahan D
    Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
    Matsumura N; Mandai M; Okamoto T; Yamaguchi K; Yamamura S; Oura T; Baba T; Hamanishi J; Kang HS; Matsui S; Mori S; Murphy SK; Konishi I
    Cancer Sci; 2010 Dec; 101(12):2658-63. PubMed ID: 21040214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma.
    Tsai LL; Bhatt RS; Strob MF; Jegede OA; Sun MRM; Alsop DC; Catalano P; McDermott D; Robson PM; Atkins MB; Pedrosa I
    Radiology; 2021 Feb; 298(2):332-340. PubMed ID: 33258745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies.
    Xiao Y; Meierhofer D
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases.
    Miyake H; Harada KI; Fujisawa M
    Int Cancer Conf J; 2018 Jan; 7(1):30-34. PubMed ID: 31149509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts.
    Chen CH; Bhasin S; Khanna P; Joshi M; Joslin PM; Saxena R; Amin S; Liu S; Sindhu S; Walker SR; Catalano P; Frank DA; Alper SL; Bhasin M; Bhatt RS
    Oncogenesis; 2019 Feb; 8(3):15. PubMed ID: 30796200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition.
    Fischl AS; Wang X; Falcon BL; Almonte-Baldonado R; Bodenmiller D; Evans G; Stewart J; Wilson T; Hipskind P; Manro J; Uhlik MT; Chintharlapalli S; Gerald D; Alsop DC; Benjamin LE; Bhatt RS
    Mol Cancer Ther; 2019 Apr; 18(4):856-867. PubMed ID: 30787172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages.
    Alsaab HO; Sau S; Alzhrani RM; Cheriyan VT; Polin LA; Vaishampayan U; Rishi AK; Iyer AK
    Biomaterials; 2018 Nov; 183():280-294. PubMed ID: 30179778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience.
    Osanto S; van der Hulle T
    Ther Adv Urol; 2018 Mar; 10(3):109-123. PubMed ID: 29662541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.
    Schwartz AD; Barney LE; Jansen LE; Nguyen TV; Hall CL; Meyer AS; Peyton SR
    Integr Biol (Camb); 2017 Dec; 9(12):912-924. PubMed ID: 29159332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney cancer: Intermittent sunitinib is an effective renal carcinoma treatment.
    Czarnecka AM
    Nat Rev Urol; 2017 May; 14(5):264-266. PubMed ID: 28266515
    [No Abstract]   [Full Text] [Related]  

  • 14. Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→︀AKT→︀GSK3β→︀AM signaling.
    Chen Y; Li C; Xie H; Fan Y; Yang Z; Ma J; He D; Li L
    Oncogene; 2017 May; 36(20):2879-2888. PubMed ID: 28114284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors.
    Wragg JW; Heath VL; Bicknell R
    Cancer Res; 2017 Feb; 77(4):1008-1020. PubMed ID: 28011623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft.
    Ukon N; Zhao S; Yu W; Shimizu Y; Nishijima KI; Kubo N; Kitagawa Y; Tamaki N; Higashikawa K; Yasui H; Kuge Y
    EJNMMI Res; 2016 Dec; 6(1):90. PubMed ID: 27957722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.
    Lambea J; Anido U; Etxániz O; Flores L; Montesa Á; Sepúlveda JM; Esteban E
    Curr Oncol Rep; 2016 Nov; 18(11):66. PubMed ID: 27613167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model.
    Diaz-Montero CM; Mao FJ; Barnard J; Parker Y; Zamanian-Daryoush M; Pink JJ; Finke JH; Rini BI; Lindner DJ
    Br J Cancer; 2016 Oct; 115(8):920-928. PubMed ID: 27560553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt Signaling in Renal Cell Carcinoma.
    Xu Q; Krause M; Samoylenko A; Vainio S
    Cancers (Basel); 2016 Jun; 8(6):. PubMed ID: 27322325
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.